Cancer Res Treat.
2007 Mar;39(1):1-5.
Induction Chemotherapy of Docetaxel and Cisplatin for the Elderly Patients with Squamous Cell Carcinoma of the Head and Neck
- Affiliations
-
- 1Department of Internal Medicine, Pusan National University College of Medicnce, Korea. hemon@pusan.ac.kr
- 2Department of Otolaryngology, Pusan National University College of Medicnce, Korea.
- 3Department of Preventive Medicine, Pusan National University College of Medicnce, Korea.
- 4Department of Radiation Oncology, Pusan National University College of Medicnce, Korea.
- 5Department of Radiology, Pusan National University College of Medicnce, Korea.
- 6Department of Internal Medicine, Inje University Hospital, Busan, Korea.
Abstract
-
PURPOSE: Although concurrent chemoradiotherapy (CCRT) has been considered as a standard treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN), this treament is associated with increased toxicities such as mucositis and dermatitis. As a result, the dose intensity can be reduced and interruptions of radiotherapy are more common for CCRT than for sequential treatment, especially for the elderly patients. This prospective study was performed to assess the efficacy and safety profiles of the induction chemotherapy of docetaxel and cisplatin for elderly patients with locally advanced SCCHN.
MATERIALS AND METHODS
Patients over 65 years of age with locally advanced SCCHN were treated with docetaxel (70 mg/m(2)) and cisplatin (75 mg/m(2)) every 21 days. The chemotherapy consisted of two cycles with a third cycle that was administered to the responding patients. Patients who did not respond to initial chemotherapy underwent radiotherapy as a definitive local treatment.
RESULTS
Fifty patients were enrolled in this study and 44 patients were assessable for response and toxicity. The overall response rate was 88%, 16 patients (36%) achieved a complete response and 23 patients (52%) achieved a partial response. After a median follow-up of 24 months (range: 9~38 months) the median disease free period and overall survival period had not yet been reached. The one year and two year survival rates were 89% and 70%, respectively. The most common grade 3/4 adverse event was neutropenia, which occurred in 33 patients (75%) and 4 patients had febrile neutropenia.
CONCLUSION
Combination chemotherapy of docetaxel and cisplatin is an effective regimen with an acceptable safety profile as the induction treatment for elderly patients suffering with SCCHN.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Induction chemotherapy in patients with locally-advanced head and neck squamous cell carcinoma: docetaxel and cisplatin
- Organ Preservation for the Management of Locally Advanced Head and Neck Cancer
- Neoadjuvant chemotherapy with 5-fluorouracial infusion and cisplatin for locally advanced, untreated squamous cell carcinoma of the head and neck
- The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer
- Establishment of Cisplatin Resistant Head and Neck Cancer Cell Lines and Cross-resistance of Docetaxel
